Description
Keytruda (Pembrolizumab) 50mg Online
Keytruda (Pembrolizumab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Keytruda can now be used to treat eligible patients whose cancer has a specific genetic alteration (a biomarker) known as deficient DNA-mismatch repair (dMMR) or microsatellite instability-high (MSI-H).
Keytruda is an antibody therapy that interferes with the activation of a molecule called PD-1. The molecule sits on the surface of immune system cells called T-lymphocytes and, when activated, prevents T-lymphocytes from destroying other cells. keytruda was approved by USA food and drug administration (FDA) on an “accelerated” basis to treat lung cancer or head and neck cancer. In clinical studies, tumors responded to this medicine. However, it has not been shown that pembrolizumab can improve symptoms or lengthen survival time.
Colorectal cancer is one form of cancer that can display the dMMR and/or MSI-H biomarker, and the new indication specifically identifies advanced colorectal cancer patients with this biomarker, whose disease has progressed following treatment with multiple therapies, as eligible for treatment. This indication was approved under the provisional approval pathway, which provides a six-year window to collect further data to support the drug’s use in MSI-H cancer and to transition to full registration. It is estimated that there are more than 20 different tumours types that may display MSI-H and/or dMMR, which can be identified through laboratory tests. These tumours include colorectal, endometrial, gastric, small intestinal, pancreatic, cholangiocarcinoma, adrenocortical, mesothelioma, small-cell lung, cervical, neuroendocrine, thyroid, urothelial, brain, ovarian, prostate, retroperitoneal, salivary, sarcoma, testicular, and tonsillar cancers.
